Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DROXIDOPA vs GIAPREZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.
Treatment of neurogenic orthostatic hypotension (n OH) in adult patients with primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, pure autonomic failure) or secondary autonomic failure (e.g., diabetes, amyloidosis)
Increase blood pressure in adults with septic or other distributive shock
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
Terminal elimination half-life is approximately 1 hour (range 0.5–2 hours); clinical context: requires continuous intravenous infusion for sustained vasopressor effect.
Metabolized by aromatic L-amino acid decarboxylase (AAAD) to norepinephrine, and also undergoes catechol-O-methyltransferase (COMT) metabolism.
Metabolized by aminopeptidase A and angiotensin-converting enzyme (ACE) to smaller fragments, including angiotensin (1-8).
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Primarily via proteolysis; renal excretion of unchanged drug is negligible (<1%). Fecal excretion is minimal.
~75% (primarily to albumin).
~70% bound to plasma proteins, primarily to albumin.
1–1.5 L/kg; indicates extensive tissue distribution.
Approximately 0.5 L/kg; indicates distribution primarily within extracellular fluid and plasma volume.
Oral: ~40% (range 30–50%) due to first-pass metabolism.
Intravenous: 100% (only route of administration; oral bioavailability is negligible due to peptide degradation).
For GFR 15-29 m L/min: reduce dose to 100 mg twice daily. For GFR <15 m L/min or dialysis: 100 mg once daily or 100 mg every other day.
No dose adjustment required for renal impairment.
No specific Child-Pugh based adjustments; contraindicated in severe hepatic impairment (Child-Pugh C). Use with caution in moderate impairment (Child-Pugh B) at reduced doses.
No dose adjustment required for hepatic impairment.
Safety and efficacy not established in pediatric patients; no standard weight-based dosing available.
Safety and efficacy not established; no FDA-approved pediatric dosing.
Start at lower end of dosing range (100 mg twice daily) due to increased risk of orthostatic hypotension and renal function decline; monitor blood pressure and adjust gradually.
No specific adjustment recommended; use with caution due to potential cardiovascular comorbidities.
No FDA black box warning.
No FDA black box warning.
May cause supine hypertension; monitor blood pressure and manage by reducing dose or discontinuing if severe.,Risk of exacerbation of cardiovascular disease (e.g., arrhythmias, heart failure).,May cause hyperthermia and confusion in patients with Parkinson's disease (resembles neuroleptic malignant syndrome).,Potential for increased risk of hallucinations or other psychiatric effects.,Use with caution in patients with pre-existing cerebrovascular or cardiovascular disease.
Thromboembolic events (venous and arterial) have been reported; monitor for signs of thrombosis.,Risk of adverse reactions from coadministration with ACE inhibitors (increased response) or angiotensin receptor blockers (increased response).,Concomitant use with vasopressors may require dose adjustment.,Not recommended for patients with high output states (e.g., cardiogenic shock) unless as a rescue therapy.
Hypersensitivity to droxidopa or any component of the formulation.,Use in patients with significant cardiovascular disease (e.g., unstable angina, recent myocardial infarction, or severe ventricular arrhythmias) is contraindicated.,Concomitant use with non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine) due to risk of hypertensive crisis.
No absolute contraindications identified.,Relative contraindications: patients with known hypersensitivity to any component; patients with a history of severe hypertension; patients with a known high risk of arterial or venous thrombosis.
Avoid alcohol as it may exacerbate hypotension. No specific food interactions known; take with or without food. High-tyramine foods (e.g., aged cheeses, cured meats) are not contraindicated but monitor blood pressure if consuming large amounts.
No known food interactions. GIAPREZA is administered intravenously and does not interact with food.
Pregnancy Category C. In animal studies, droxidopa caused decreased fetal weights and increased skeletal variations at doses 2.6 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum recommended human dose based on AUC. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: limited data; second and third trimesters: theoretical risk of fetal hypotension and hypoperfusion due to maternal hypotension.
No data available on presence in human milk, effects on breastfed infant, or milk production. Caution advised. M/P ratio unknown.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Consider developmental and health benefits of breastfeeding along with mother's clinical need for angiotensin II and any potential adverse effects on breastfed infant from drug or underlying maternal condition. M/P ratio not available.
No specific pharmacokinetic data in pregnancy; dose adjustment not recommended due to lack of evidence. Use lowest effective dose. Monitor for hypotension and supine hypertension.
No specific dose adjustments recommended for pregnancy. Dose titration based on blood pressure response as in non-pregnant adults. Limited data on pharmacokinetic changes in pregnancy; consider potential increased volume of distribution and altered clearance, but no established dose modification.
Droxidopa is a prodrug of norepinephrine used for symptomatic neurogenic orthostatic hypotension (NOH). Monitor supine hypertension closely; advise patients to avoid dose lying down. Onset of action is within 1 hour, peak effect at 3-4 hours, duration about 6-8 hours. Titrate based on symptoms and supine blood pressure. Do not administer within 5 hours of bedtime to reduce risk of nocturnal supine hypertension. Can be used with fludrocortisone or midodrine, but additive hypertension risk.
GIAPREZA (angiotensin II) is indicated for the treatment of refractory hypotension in adults with distributive shock who have failed adequate volume resuscitation and other vasopressors. Do not administer with angiotensin-converting enzyme (ACE) inhibitors due to risk of excessive hypotension. Monitor blood pressure continuously during administration. Prepare using strict aseptic technique; discard unused portion. Dosage is based on the patient's baseline mean arterial pressure (MAP) and response. Use with caution in patients with severe hypertension or conditions that may be exacerbated by vasoconstriction.
Take droxidopa exactly as prescribed, usually three times daily: on waking, mid-day, and late afternoon—never within 5 hours of bedtime.,Do not lie down after taking a dose; remain upright (sitting or standing) to prevent severe high blood pressure while lying down.,Rise slowly from sitting or lying positions to reduce falls; symptoms of low blood pressure include dizziness, lightheadedness, and fainting.,Avoid alcohol, which can worsen low blood pressure and increase side effects like dizziness.,Report symptoms of high blood pressure when lying down: severe headache, blurred vision, chest pain, difficulty breathing.,Store at room temperature; keep away from moisture and heat.
This medication is used to increase your blood pressure if it is dangerously low and not responding to other treatments.,Your blood pressure will be monitored continuously during the infusion.,Inform your healthcare provider if you have a history of high blood pressure, heart disease, or any allergies.,Do not stop or change the dose without consulting your doctor.,Report any symptoms such as chest pain, shortness of breath, or headache immediately.
"Betahistine, a histamine analog, may reduce the therapeutic efficacy of droxidopa, a prodrug converted to norepinephrine for the treatment of symptomatic neurogenic orthostatic hypotension. The proposed physiological effect is that betahistine's H1- and H3-receptor agonistic and antagonistic activities could counteract the pressor response of norepinephrine, leading to suboptimal blood pressure elevation. Clinically, this may result in inadequate control of orthostatic hypotension symptoms, such as dizziness and syncope, when both agents are used concomitantly."
"Droxidopa, a synthetic amino acid converted to norepinephrine, directly elevates blood pressure, opposing the antihypertensive effects of mirtazapine. Mirtazapine, an atypical antidepressant with alpha-2 antagonism, may further enhance norepinephrine release, potentially synergizing with droxidopa's pressor effect. This interaction can lead to reduced efficacy of mirtazapine in managing hypertension and may increase risk of hypertensive crisis."
"Droxidopa, a prodrug of norepinephrine, is used to increase blood pressure in patients with neurogenic orthostatic hypotension. Tianeptine, an atypical antidepressant with opioid receptor activity, can cause bradycardia and hypotension. The combination may lead to an antagonistic effect where tianeptine's hypotensive properties reduce the pressor efficacy of droxidopa, potentially resulting in inadequate blood pressure control and recurrence of orthostatic hypotension symptoms."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DROXIDOPA vs GIAPREZA, answered by our medical review team.
DROXIDOPA is a Vasopressor that works by Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.. GIAPREZA is a Vasopressor that works by A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DROXIDOPA and GIAPREZA depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DROXIDOPA is: 100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.. The standard adult dose of GIAPREZA is: 1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DROXIDOPA and GIAPREZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DROXIDOPA is classified as Category C. Pregnancy Category C. In animal studies, droxidopa caused decreased fetal weights and increased skeletal variations at doses 2.6 times the maximum recommended human dose. There are. GIAPREZA is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum reco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.